Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II. J Am Coll Radiol 2011 May;8(5):302-8

Date

05/03/2011

Pubmed ID

21531305

DOI

10.1016/j.jacr.2011.01.009

Abstract

Combined-modality therapy, consisting of chemotherapy followed by radiation therapy (RT), represents the standard of care for most patients with unfavorable-prognosis early-stage Hodgkin's lymphoma. The most widely accepted chemotherapy regimen is ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine); however, recent trials have evaluated other regimens such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V. After chemotherapy, the standard radiation field is involved-field RT, although there is increasing interest now in involved-node RT. The authors review recent trials on chemotherapy and RT for unfavorable-prognosis early-stage Hodgkin's lymphoma. This article presents illustrative clinical cases, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists.

Author List

Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ

Author

Cindy L. Schwartz MD, MPH Chief, Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Hodgkin Disease
Humans
Medical Oncology
Neoplasm Staging
Practice Guidelines as Topic
Radiology
Societies, Medical
United States
jenkins-FCD Prod-461 7d7c6113fc1a2757d2947d29fae5861c878125ab